NASDAQ:ATAI Atai Life Sciences (ATAI) Stock Price, News & Analysis $1.21 -0.07 (-5.47%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Atai Life Sciences Stock (NASDAQ:ATAI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Atai Life Sciences alerts:Sign Up Key Stats Today's Range$1.20▼$1.2850-Day Range$1.06▼$1.3352-Week Range$1.03▼$2.85Volume396,759 shsAverage Volume1.11 million shsMarket Capitalization$202.56 millionP/E RatioN/ADividend YieldN/APrice Target$10.50Consensus RatingBuy Company OverviewAtai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Read More… Urgent: This election is rigged (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Atai Life Sciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks45th Percentile Overall ScoreATAI MarketRank™: Atai Life Sciences scored higher than 45% of companies evaluated by MarketBeat, and ranked 631st out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAtai Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtai Life Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Atai Life Sciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Atai Life Sciences are expected to grow in the coming year, from ($0.78) to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atai Life Sciences is -3.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atai Life Sciences is -3.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtai Life Sciences has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Atai Life Sciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.10% of the float of Atai Life Sciences has been sold short.Short Interest Ratio / Days to CoverAtai Life Sciences has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.Change versus previous monthShort interest in Atai Life Sciences has recently decreased by 1.56%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtai Life Sciences does not currently pay a dividend.Dividend GrowthAtai Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.10% of the float of Atai Life Sciences has been sold short.Short Interest Ratio / Days to CoverAtai Life Sciences has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.Change versus previous monthShort interest in Atai Life Sciences has recently decreased by 1.56%, indicating that investor sentiment is improving. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 4 people have searched for ATAI on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows2 people have added Atai Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Atai Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,093,000.00 in company stock.Percentage Held by Insiders31.20% of the stock of Atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.41% of the stock of Atai Life Sciences is held by institutions.Read more about Atai Life Sciences' insider trading history. Receive ATAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ATAI Stock News HeadlinesATAI Life Sciences (NASDAQ:ATAI) Stock, Insider Trading ActivityOctober 15, 2024 | benzinga.comatai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 15, 2024 | finance.yahoo.comUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says YesOctober 8, 2024 | benzinga.comATAI Life Sciences completes acquisition of IntelGenx Corp.October 6, 2024 | investing.comIntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AGOctober 2, 2024 | globenewswire.comAtai Life Sciences N.V. (9VC.DE)September 18, 2024 | sg.finance.yahoo.comBiologists find that hardship early in life can affect health and longevity—even for marmotsSeptember 17, 2024 | msn.comSee More Headlines ATAI Stock Analysis - Frequently Asked Questions How have ATAI shares performed this year? Atai Life Sciences' stock was trading at $1.41 at the beginning of 2024. Since then, ATAI shares have decreased by 14.2% and is now trading at $1.21. View the best growth stocks for 2024 here. How were Atai Life Sciences' earnings last quarter? Atai Life Sciences (NASDAQ:ATAI) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.20. The firm had revenue of $0.27 million for the quarter. When did Atai Life Sciences IPO? Atai Life Sciences (ATAI) raised $200 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 14,300,000 shares at $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg served as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers. How do I buy shares of Atai Life Sciences? Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Atai Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atai Life Sciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), CrowdStrike (CRWD) and ServiceNow (NOW). Company Calendar Last Earnings8/13/2024Today10/24/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATAI CUSIPN/A CIK1420529 Webwww.atai.net.cn Phone49-89-2153-9035FaxN/AEmployees83Year FoundedN/APrice Target and Rating Average Stock Price Target$10.50 High Stock Price Target$15.00 Low Stock Price Target$6.00 Potential Upside/Downside+767.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,220,000.00 Net MarginsN/A Pretax Margin-15,140.21% Return on Equity-56.19% Return on Assets-46.78% Debt Debt-to-Equity Ratio0.12 Current Ratio6.68 Quick Ratio6.68 Sales & Book Value Annual Sales$378,000.00 Price / Sales535.88 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book0.82Miscellaneous Outstanding Shares167,406,000Free Float115,446,000Market Cap$202.56 million OptionableOptionable Beta0.78 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:ATAI) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atai Life Sciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Atai Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.